Targeting the Microenvironment in MDS: The Final Frontier.

Teodorescu, Patric; Pasca, Sergiu; Dima, Delia; Tomuleasa, Ciprian; Ghiaur, Gabriel

Teodorescu, Patric; Pasca, Sergiu; Dima, Delia; Tomuleasa, Ciprian; Ghiaur, Gabriel.

Afiliação

Teodorescu P; Department of Hematology, Iuliu Hategan University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Pasca S; Department of Oncology, The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, MD, United States.
Dima D; Department of Hematology, Iuliu Hategan University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Tomuleasa C; Department of Hematology, Iuliu Hategan University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ghiaur G; Department of Hematology, Iuliu Hategan University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Front Pharmacol ; 11: 1044, 2020.

Article em En | MEDLINE | ID: mdl-32742264

Palavras-chave

CYP26 enzymes; all-trans retinoic acid; azacytidine; lenalidomide; luspatercept; microenvironment; myelodyslastic syndromes; rigosertib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article